Who
James Aloysius Brady
Director
Company insider
Files Form 4 as: Director, Xeris Biopharma Holdings; Director, Verona Pharma.
In numbers
- Trades disclosed
- 21
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $131K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 14 Mar 2022
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Jul 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —24,193 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | $203K32,996 at $6.15 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | $203K32,996 at $6.15 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —24,193 at $0.00 | filing |
| 30 Mar 2026filed 1 Apr 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $60K10,834 at $5.54 | filing |
| 30 Mar 2026filed 1 Apr 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $60K10,834 at $5.54 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —72,000 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code D | —288,000 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code D | —96,000 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code D | —240,000 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharma | SEC FORM 4 Code D | —23,176 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharma | SEC FORM 4 Code M | —72,000 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharma | SEC FORM 4 Code D | —72,000 | filing |
| 1 Aug 2025filed 5 Aug 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | Verona Pharma | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | Verona Pharma | SEC FORM 4 Sold | $11K824 at $13.14 | filing |
| 25 Apr 2025filed 29 Apr 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code A | —96,000 at $0.00 | filing |
| 28 Mar 2025filed 28 Mar 2025 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 29 Apr 2024filed 30 Apr 2024 | Verona Pharmaoption or derivative | SEC FORM 4 Code A | —240,000 at $0.00 | filing |
| 28 Apr 2023filed 28 Apr 2023 | Verona Pharmaoption or derivative | SEC FORM 4 Code A | —96,000 at $0.00 | filing |
News
Head-To-Head Survey: Organon & Co. (NYSE:OGN) versus Xeris Biopharma (NASDAQ:XERS)XERS · themarketsdaily.com · 19 Oct 2026Comparing Corcept Therapeutics (NASDAQ:CORT) & Xeris Biopharma (NASDAQ:XERS)XERS · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name James Aloysius Brady; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.